Suven Life Sciences, a company in the Healthcare Research, Analytics & Technology industry, reported revenue of ₹1.00 crore and a net loss of ₹107 crore for the September 2026 quarter.
Suven Life Sciences (NSE: SUVEN) closed at ₹269.40 on 20 Nov 2026, up 52.1% over the past year. Its market capitalisation is ₹7,612 crore.
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.